Zoetis (ZTS) Return on Capital Employed (2013 - 2026)
Zoetis (ZTS) reported Return on Capital Employed of 27.58% for Q1 2026, down 494.0% year-over-year from 7.0% in Q1 2025, and down 1.18% quarter-over-quarter from 27.91% in Q4 2025.
Zoetis (ZTS) Return on Capital Employed (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has 14 years of Return on Capital Employed data on file, last reported at 27.58% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 27.58%, down 494.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.58% (down 494.0% YoY), and the FY2025 annual result was 28.97%, down 320.0% from the prior year.
- Return on Capital Employed declined to 27.58% in Q1 2026 per ZTS's latest filing, from 27.91% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 33.19% in Q2 2025 and troughed at 24.05% in Q1 2023.
- A 5-year average of 27.81% and a median of 27.54% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed jumped 2602 bps in 2022, then slumped 494 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 27.59% in 2022, then dropped by 7 bps to 25.77% in 2023, then climbed by 24 bps to 32.06% in 2024, then decreased by 13 bps to 27.91% in 2025, then dropped by 1 bps to 27.58% in 2026.
- Business Quant data shows ZTS's Return on Capital Employed at 27.58% in Q1 2026, 27.91% in Q4 2025, and 27.91% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 6.92% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 14.85% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -1.92% |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.58% |
| Dec 31, 2025 | 27.91% |
| Sep 30, 2025 | 27.91% |
| Jun 30, 2025 | 33.19% |
| Mar 31, 2025 | 32.52% |
| Dec 31, 2024 | 32.06% |
| Sep 30, 2024 | 27.33% |
| Jun 30, 2024 | 26.45% |
| Mar 31, 2024 | 26.23% |
| Dec 31, 2023 | 25.77% |
| Sep 30, 2023 | 25.61% |
| Jun 30, 2023 | 25.78% |
| Mar 31, 2023 | 24.05% |
| Dec 31, 2022 | 27.59% |
| Sep 30, 2022 | 27.54% |
| Jun 30, 2022 | 27.79% |
| Mar 31, 2022 | 27.41% |
| Dec 31, 2021 | 16.78% |
| Sep 30, 2021 | 15.49% |
| Jun 30, 2021 | 8.80% |